SMC decision expands options for people with chronic itch

Gilead Sciences (Nasdaq: GILD) reported second quarter 2026 revenues of $7.8 billion, up 10% year-over-year, with total product sales of $7.6 billion. Product sales excluding Veklury rose 10%, driven by HIV, Trodelvy and Livdelzi, while Veklury declined 81% to $23 million.HIV revenue increased 12% to $5.7 billion, including Biktarvy up 7% to $3.8 billion and Descovy up 48% to $967 million. Trodelvy sales grew 26% to $457 million, while Cell Therapy fell 14% to $417 million. Diluted loss per share was $(8.45) and non-GAAP diluted loss per share was $(6.75), mainly reflecting $11.2 billion of acquired IPR&D expenses from the Arcellx, Tubulis and Ouro Medicines deals.Cash, cash equivalents and marketable debt securities were $3.2 billion at June 30, 2026 versus $10.6 billion at year-end 2025, after $11.3 billion of acquisition-related outflows. Gilead updated 2026 guidance, slightly raising product sales excluding Veklury, cutting expected Veklury sales to about $300 million and reaffirming a full-year GAAP and non-GAAP loss per share including roughly $9.08 of IPR&D-related impact.

Gilead Sciences just hit Korea’s accelerator with Livdelzi (seladelpar) -- and Ipsen’s rival Iqirvo (elafibranor) may be inching toward the line, too, according to a local report -- injecting rivalry into a rare-liver field that barely stirred a year ago.The Ministry of Food and Drug Safety (MFDS) o

Gilead Sciences just hit Korea’s accelerator with Livdelzi (seladelpar) -- and Ipsen’s rival Iqirvo (elafibranor) may be inching toward the line, too, according to a local report -- injecting rivalry into a rare-liver field that barely stirred a year ago.The Ministry of Food and Drug Safety (MFDS) o

Gilead Sciences just hit Korea’s accelerator with Livdelzi (seladelpar) -- and Ipsen’s rival Iqirvo (elafibranor) may be inching toward the line, too, according to a local report -- injecting rivalry into a rare-liver field that barely stirred a year ago.The Ministry of Food and Drug Safety (MFDS) o

Gilead Sciences just hit Korea’s accelerator with Livdelzi (seladelpar) -- and Ipsen’s rival Iqirvo (elafibranor) may be inching toward the line, too, according to a local report -- injecting rivalry into a rare-liver field that barely stirred a year ago.The Ministry of Food and Drug Safety (MFDS) o

Gilead Sciences (NASDAQ:GILD) executives outlined the company’s approach to next-generation HIV medicines, ongoing commercialization efforts in liver disease, and a broad slate of oncology and inflammation programs during a discussion hosted by Leerink Partners analyst Daina Graybosch. HIV: Moving

1. Gilead reported positive phase 3 IDEAL data for seladelpar (Livdelzi) in patients with primary biliary cholangitis who had persistent alkaline phosphatase elevation. 2. The findings support a broader treatment goal in primary biliary cholangitis, moving beyond partial biochemical improvement toward normalization of disease markers. Gilead has reported positive phase 3 IDEAL data for seladelpar

Gilead has touted Livdelzi's potential in patients with high ALP levels, potentially expanding the drug’s reach across the PBC indication.

If approved Zydus' saroglitazar would go head-to-head with Gilead’s Livdelzi and Ipsen’s Iqirvo in the highly competitive PBC market.

– Analysis of Phase 3 ASSURE Study Finds Livdelzi Shows Promising Data on Liver Stiffness in PBC Patients After 3 Years – – Livdelzi Data in PBC Participants Provide Outcomes for Long-Term Biochemical Response, which Slows Disease Progression and Sustained...